Please select the option that best describes you:
How do you determine whether to choose a non-anthracycline neoadjuvant chemotherapy regimen in a fit patient with TNBC?
Does the KN-522 data change your decision about chemo regimen?
Answer from: Medical Oncologist at Community Practice
Optimal neoadjuvant chemotherapy (NAC) regimen for TNBC has not been established and treatment regimens are usually mirrored from adjuvant trials. When choosing neoadjuvant chemotherapy regimen, the goal should be to achieve pathological complete response (pCR), since patients who do not achieve a p...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
There were several interesting updates on this topic at the SABCS last week: GeparX (neodjuvant Carbo/nab-paclitaxel with different nab-paclitaxel schedules, followed by EC then surgery) and two IO trials, KEYNOTE-522 (neoadjuvant Pembro/Carbo/Taxol followed by Pembro/AC-->Surgery) and NeoTRIP (n...
Answer from: Medical Oncologist at Academic Institution
I have to disagree with both of the answers submitted thus far. While I will occasionally administer TC (docetaxel and cyclophosphamide) x 4 in the adjuvant setting in low risk (T1N0) TNBC, in the neoadjuvant setting I prefer to include carboplatin, especially if trying to avoid giving an anthracycl...